Dr. Robert Soler: Specialist in advanced therapy medicinal products based on Cultured Mesenchymal Cells (CMC)

CEO and Medical Director at ITRT, with more than 20 years of clinical experience in the personalized and regulated application of cell-based medicinal products authorized by the Spanish Agency of Medicines and Medical Devices (AEMPS), specialized in musculoskeletal and tissue-related pathologies.

Dr. Robert Soler Director Médico del ITRT

Committed to safe, regulated, advanced cell-based medicine.

Screenshot 2025-12-11 114602

Dr. Robert Soler’s clinical activity focuses on the regulated application of advanced cell therapy medicinal products based on Cultured Mesenchymal Cells (CMC) in complex musculoskeletal injuries.

His approach is based on a comprehensive medical evaluation of the affected tissue and the patient’s functional status, in order to define personalized interventions within the established legal and regulatory framework.

At ITRT, he leads the individualized clinical strategy associated with each cell-based medicinal product authorized by the Spanish Agency of Medicines and Medical Devices (AEMPS), integrating clinical practice and clinical research under the highest standards of quality and regulatory compliance.

Scientific career and international leadership

Since 1998, Dr. Robert Soler has carried out his clinical work at Centro Médico Teknon, where he has led the clinical development of advanced cell therapy medicinal products based on Cultured Mesenchymal Cells (CMC). As CEO and Medical Director of ITRT, he has taken part as an investigator in more than 20 trials, most of them authorized clinical trials in patients.

Currently, ITRT applies regulated cell-based medicinal products in pathologies such as osteoarthritis, tendinopathies, disc diseases, pseudoarthrosis, osteonecrosis, and xerostomia. The institute continues to advance new indications within the current regulatory framework.

circulo

Dr. Robert Soler is a member of the Advanced Therapies Committee at Centro Médico Teknon, collaborates with European scientific networks, and is a regular speaker at international conferences on advanced cell-based medicinal products and healthcare regulation.

Dr. Robert Soler: a career dedicated to advancing medical science

Co-founder and Medical Director of ITRT, a pioneering center in the regulated development of advanced cell therapy medicinal products based on Cultured Mesenchymal Cells (CMC).

Principal investigator and co-investigator in clinical trials authorized by the Spanish Agency of Medicines and Medical Devices (AEMPS) in chronic tendinopathies, articular cartilage injuries, lumbar and cervical disc diseases, pseudoarthrosis, bone necrosis, and xerostomia.

More than twenty years of clinical and research experience in advanced cell therapy medicinal products applied to musculoskeletal and tissue-related pathologies.

Author and co-author in high-impact international journals, with relevant contributions to tendon, cartilage, and intervertebral disc regeneration, among other areas.

Member of the Advanced Therapies Committee at Centro Médico Teknon and collaborator in European scientific networks focused on cell-based research.

Regular speaker at international conferences on advanced cell therapy medicinal products, European healthcare regulation, and the clinical application of Cultured Mesenchymal Cells (CMC).

International leadership in advanced cell therapy medicinal products

terapias celulares avanzadas en el ITRT con el Dr. Robert Soler
510f69c107ed37283c02a123b8fec748351af4cc 1

Dr. Robert Soler has led a clinical and scientific career with international impact, positioning ITRT as a benchmark in advanced cell therapy medicinal products. For more than twenty years, he has treated patients from around the world, including professional athletes and individuals with complex degenerative conditions, through authorized and personalized cell-based medicinal products, always within a regulated framework.

This care model has contributed to the recovery of function and quality of life in numerous patients, consolidating a medical approach based on evidence, safety, and regulation.

Advanced cell therapy medicinal products based on Cultured Mesenchymal Cells (CMC) are subject to medical prescription and require individual authorization from the Spanish Agency of Medicines and Medical Devices (AEMPS).
The information presented here is for informational purposes only and does not replace medical consultation or the recommendations of a healthcare professional.

Dr. Robert Soler has authored and co-authored more than 15 scientific publications in high-impact, indexed international journals. His work has been published in:

  • Transplantation (Impact Factor: 5.3)
  • The Knee (international reference journal in orthopedic surgery)
  • American Journal of Sports Medicine (AJSM) – leading journal in sports medicine
  • Orthopaedic Journal of Sports Medicine (OJSM)
  • Journal of Translational Medicine (translational research)
  • Biomedicines (advanced therapies)
afcf311b72b4d6c495fa9837bea37b83bee31b9c (1)

The new medicine: evidence, regulation, and safety

afcf311b72b4d6c495fa9837bea37b83bee31b9c (1)

In an environment where unauthorized treatments proliferate under ambiguous terms such as “regenerative medicine” or “immediate stem cells,” Dr. Robert Soler and the ITRT team represent the new medicine: personalized, based on scientific evidence, and subject to strict regulation by the Spanish Agency of Medicines and Medical Devices (AEMPS). A clinical model that prioritizes safety, traceability, and validated efficacy.

“Not all cell-based treatments are medicinal products. Only those developed under GMP standards, with individual authorization from the Spanish Agency of Medicines and Medical Devices (AEMPS) and regulated clinical evidence, can be considered part of the new, safe, regulated, and validated cell-based medicine.”

— Dr. Robert Soler, CEO and Medical Director of ITRT

Blog

Artículos